Wallaby Medical Holding, Inc. ("Wallaby") is a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke. Established in 2015, we currently have over 250 employees located in Laguna Hills, California and Shanghai, China.
We develop and produce some of the most reliable and technologically advanced products supported by proven clinical data. Our commercialized product portfolio includes the Avenir® Coil System, a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, the Esperance™ Aspiration Catheters for use in the revascularization of patients with acute ischemic stroke, and the Esperance™ Distal Access Catheter for general intravascular usage including neuro.
We market our products in over 60 countries and regions around the world, including the U.S., China, Europe and Japan. In addition, we have a full range of neurovascular interventional products currently under development.
0
+Licensed countries/regions
17
,000
+㎡
Office, R&D and manufacturing
2023-02-06
more>2022-04-21
more>2022-04-23
more>2022-04-02
more>2021-12-03
more>2021-09-26
more>2021-08-23
more>2020-11-26
more>2020-05-06
more>2022-09-09
more>2023-02-06
more>2022-04-21
more>2022-04-23
more>2022-04-02
more>2021-12-03
more>2021-09-26
more>2021-08-23
more>2020-11-26
more>2020-05-06
more>2022-09-09
more>Wallaby Medical phenox Obtained FDA 510k Clearance for its pRESET Thrombectomy Device
Wallaby/phenox announces global launch of the pEGASUS HPC Stent System — the first laser-cut, open-cell stent device with antithrombogenic HPC coating technology
Avenir® Plus Coil System Approved by NMPA
Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion
Esperance™ 6F Aspiration Catheter obtained NMPA approval
Setup strategic partnership with Japan Lifeline to achieve a larger scale of development in the Japanese market
Esperance™ 5F & 6F Aspiration Catheter obtained FDA 510(k) clearance.
Phase 1 of new Shanghai Xingchuang Park facility completed
Avenir® Coil System obtained NMPA registration approval and was listed in the Innovative Medical Device Product List, China
Development path
Wallaby Medical phenox Obtained FDA 510k Clearance for its pRESET Thrombectomy Device
Wallaby/phenox announces global launch of the pEGASUS HPC Stent System — the first laser-cut, open-cell stent device with antithrombogenic HPC coating technology
Avenir® Plus Coil System Approved by NMPA
Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion
Esperance™ 6F Aspiration Catheter obtained NMPA approval
Setup strategic partnership with Japan Lifeline to achieve a larger scale of development in the Japanese market
Esperance™ 5F & 6F Aspiration Catheter obtained FDA 510(k) clearance.
Phase 1 of new Shanghai Xingchuang Park facility completed
Avenir® Coil System obtained NMPA registration approval and was listed in the Innovative Medical Device Product List, China
Development path
©2022 Wallaby Medical. All Rights Reserved | Privacy Statement Official Wechat
©2022 Wallaby Medical. All Rights Reserved
Privacy Statement
Official Wechat